Prescient Therapeutics Ltd
ASX:PTX

Watchlist Manager
Prescient Therapeutics Ltd Logo
Prescient Therapeutics Ltd
ASX:PTX
Watchlist
Price: 0.043 AUD -2.27% Market Closed
Updated: May 20, 2024

Prescient Therapeutics Ltd
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prescient Therapeutics Ltd
Research & Development Peer Comparison

Comparables:
IMM
MSB
CSL
CUV
TLX

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Prescient Therapeutics Ltd
ASX:PTX
Research & Development
-AU$7.8m
CAGR 3-Years
-41%
CAGR 5-Years
-24%
CAGR 10-Years
-95%
Immutep Ltd
ASX:IMM
Research & Development
-AU$37.7m
CAGR 3-Years
-31%
CAGR 5-Years
-24%
CAGR 10-Years
-11%
Mesoblast Ltd
ASX:MSB
Research & Development
-$25.7m
CAGR 3-Years
N/A
CAGR 5-Years
17%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Research & Development
-$1.3B
CAGR 3-Years
-14%
CAGR 5-Years
-12%
CAGR 10-Years
-11%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Research & Development
-AU$1.4m
CAGR 3-Years
-33%
CAGR 5-Years
21%
CAGR 10-Years
5%
Telix Pharmaceuticals Ltd
ASX:TLX
Research & Development
-AU$128.8m
CAGR 3-Years
-77%
CAGR 5-Years
-47%
CAGR 10-Years
N/A

See Also

What is Prescient Therapeutics Ltd's Research & Development?
Research & Development
-7.8m AUD

Based on the financial report for Dec 31, 2023, Prescient Therapeutics Ltd's Research & Development amounts to -7.8m AUD.

What is Prescient Therapeutics Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-95%

Over the last year, the Research & Development growth was -84%. The average annual Research & Development growth rates for Prescient Therapeutics Ltd have been -41% over the past three years , -24% over the past five years , and -95% over the past ten years .